What do systematic reviews say?

PAP therapy vs usual care

• Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1412 participants
  Low

ICD plus optimal medical therapy vs optimal medical therapy alone

• Implantable cardiac defibrillators for people with non‐ischaemic cardiomyopathy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1116 participants
  Moderate

Ranolazine (monotherapy) vs placebo

It is very uncertain whether ranolazine (monotherapy) changes adverse events incidence compared with placebo (very low certainty).

• Ranolazine for stable angina pectoris 2017 · Cochrane Headline outcomes only
  RR 1.5 [1.12, 2]
  3 studies · 947 participants
  Very low

Ranolazine (add‐on therapy) vs placebo

Ranolazine (add‐on therapy) probably leads to higher adverse events incidence compared with placebo (moderate certainty).

• Ranolazine for stable angina pectoris 2017 · Cochrane Headline outcomes only
  RR 1.22 [1.06, 1.4]
  3 studies · 2123 participants
  Moderate

Implantable cardioverter defibrillators vs beta‐blocker

Implantable cardioverter defibrillators showed no clear difference in adverse events compared with β‐blocker therapy (low certainty).

• Implantable defibrillators versus medical therapy for cardiac channelopathies 2015 · Cochrane Headline outcomes only
  RR 2.44 [0.92, 6.44]
  2 studies · 86 participants
  Low

Coenzyme Q10 vs placebo or conventional therapy

Coenzyme Q10 showed no clear difference in adverse events compared with placebo or conventional therapy (low certainty).

• Coenzyme Q10 for heart failure 2021 · Cochrane Headline outcomes only
  RR 0.7 [0.45, 1.1]
  2 studies · 568 participants
  Low

Intervention not reported

• Stem cell therapy for chronic ischaemic heart disease and congestive heart failure 2016 · Cochrane Headline outcomes only
  no estimate extracted
  34 studies · 1695 participants
  GRADE not reported